Increase in Lifestyle Diseases to Boost the Global Anticoagulant Market Through 2021, Reports Technavio

Technavio has published a new report on the global anticoagulant market from 2017-2021. (Photo: Business Wire)

???pagination.previous??? ???pagination.next???

LONDON--()--Technavio market research analysts forecast the global anticoagulant market to grow at a CAGR of more than 7% during the forecast period, according to their latest report.

The market study covers the present scenario and growth prospects of the global anticoagulant market for 2017-2021. The report also lists Factor Xa inhibitors, Direct thrombin inhibitors (DTIs), Heparin, and Vitamin K antagonists as the four major segments based on drug class, of which the Factor Xa inhibitors accounted for around 53% of the market share in 2016.

According to Sapna Jha, a lead analyst at Technavio for infectious and rare diseases research, “The market is expected to witness a paradigm shift towards novel oral anticoagulants, owing to increased benefits such as rapid action, better safety, and efficacy profiles. The launch of anti-reversal agents such as PRAXBIND will further supplement the growth of NOACs.”

Request a sample report: http://www.technavio.com/request-a-sample?report=56821

Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.

Technavio healthcare and life sciences analysts highlight the following three market drivers that are contributing to the growth of the global anticoagulant market:

  • Increasing demand for NOACs
  • Growing prevalence of coagulation disorders
  • Increase in hip and knee surgeries

Increasing demand for NOACs

The increasing adoption rates of novel oral anticoagulant (NOACs) is driving the market growth. NOACs target either thrombin or factor Xa to prevent and treat thrombosis. They show quick action and do not require continuous monitoring. They also have better safety and efficacy profiles when compared with conventional therapies such as warfarin. Hence, the adoption rate of NOACs has witnessed a significant increase, to the extent of 62% of all the anticoagulant prescriptions were being written for novel oral anticoagulant during 2010-2013.

Growing prevalence of coagulation disorders

Due to unhealthy lifestyle and lack of physical activities, people are facing cardiovascular disorders, kidney disorders, and strokes. According to the CDC 2015 report, approximately 900,000 people are affected by deep vein thrombosis (DVT) or pulmonary embolism (PE), and 60,000-100,000 individuals die of this condition every year in the US. Also, over 10% of the adults in the US, are affected with kidney diseases, which are commonly associated with thrombosis. This leads to embolus, where the clot can break free and travel through the blood vessels, obstructing the normal blood flow. This condition is treated using an anticoagulant.

“The increasing number of surgeries for various diseases increase the risk of developing DVT. Thus, the rising prevalence of these diseases propels the growth of the anticoagulant market during the forecast period,” says Sapna.

Increase in hip and knee surgeries

The increase in hip and knee replacement surgeries can also increase the risk of DVT, which is likely to drive the market. Surgeries often result in long periods of immobility, increasing the chances of developing DVT due to reduced blood flow. It is reported that over a million Americans undergo joint replacement surgeries every year. Individuals undergoing knee replacement and hip replacement surgeries have an increased likelihood of developing DVT. The increasing number of surgical procedures would increase the chances of developing thromboembolic events after surgeries grow, thus requiring treatment using anticoagulants.

Browse Related Reports:

Become a Technavio Insights member and access all three of these reports for a fraction of their original cost. As a Technavio Insights member, you will have immediate access to new reports as they’re published in addition to all 6,000+ existing reports covering segments like life science research tools; medical imaging; and men’s health, women’s health and genitourinary. This subscription nets you thousands in savings, while staying connected to Technavio’s constant transforming research library, helping you make informed business decisions more efficiently.

About Technavio

Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.

Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users.

If you are interested in more information, please contact our media team at media@technavio.com.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com

Release Summary

Technavio market research analysts forecast the global anticoagulant market to grow at a CAGR of more than 7% during the forecast period, according to their latest report.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com